sarilumab SAR153191 (REGN88)
PDY14191
Phase 1 small_molecule completed
Quick answer
sarilumab SAR153191 (REGN88) for Rheumatoid Arthritis is a Phase 1 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pasteur
- Indication
- Rheumatoid Arthritis
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed